Summit Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos de Summit Therapeutics aumenten en un 77.1% al año.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.2%
Tasa de crecimiento de los ingresos	77.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	25 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:SMMT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	10	N/A	-308	-249	1
12/31/2025	N/A	N/A	-216	-172	1
12/31/2024	N/A	N/A	-156	-120	1
12/31/2023	N/A	-615	-552	-77	N/A
9/30/2023	N/A	-598	-52	-52	N/A
6/30/2023	0	-598	-46	-46	N/A
3/31/2023	0	-600	-36	-36	N/A
12/31/2022	1	-79	-42	-42	N/A
9/30/2022	1	-87	-57	-56	N/A
6/30/2022	2	-85	-72	-71	N/A
3/31/2022	2	-93	-72	-71	N/A
12/31/2021	2	-89	-73	-73	N/A
9/30/2021	2	-75	-72	-71	N/A
6/30/2021	1	-73	-65	-64	N/A
3/31/2021	1	-64	-64	-64	N/A
12/31/2020	1	-53	-49	-48	N/A
9/30/2020	1	-51	-49	-49	N/A
6/30/2020	1	-40	-38	-37	N/A
3/31/2020	-5	-31	-18	-18	N/A
12/31/2019	1	-32	-23	-23	N/A
10/31/2019	26	-28	-24	-23	N/A
7/31/2019	24	-27	-20	-19	N/A
4/30/2019	72	12	-24	-24	N/A
1/31/2019	57	11	-35	-35	N/A
10/31/2018	70	2	-36	-36	N/A
7/31/2018	72	11	-45	-45	N/A
4/30/2018	27	-29	-19	-19	N/A
1/31/2018	20	-29	-21	-21	N/A
10/31/2017	15	-18	N/A	-20	N/A
7/31/2017	12	-23	N/A	31	N/A
4/30/2017	5	-27	N/A	14	N/A
1/31/2017	3	-27	N/A	15	N/A
10/31/2016	1	-29	N/A	15	N/A
7/31/2016	1	-33	N/A	-26	N/A
4/30/2016	1	-32	N/A	-29	N/A
1/31/2016	2	-29	N/A	-24	N/A
10/31/2015	2	-25	N/A	-23	N/A
7/31/2015	3	-20	N/A	-20	N/A
4/30/2015	3	-19	N/A	-21	N/A
1/31/2015	3	-17	N/A	-17	N/A
10/31/2014	3	-17	N/A	-16	N/A
7/31/2014	4	-17	N/A	-16	N/A
4/30/2014	4	-13	N/A	-11	N/A
1/31/2014	3	-10	N/A	-10	N/A
10/31/2013	0	-8	N/A	-6	N/A
7/31/2013	2	-6	N/A	-5	N/A
4/30/2013	2	-7	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de SMMT es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de SMMT crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de SMMT crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que SMMT no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que SMMT no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SMMT se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Summit Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Summit Therapeutics Inc., Annual General Meeting, Jun 14, 2024

Summit Therapeutics Inc. to Report Q1, 2024 Results on May 01, 2024

Less than half of directors are independent

Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors

Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer

Co-CEO, President & Director recently bought US$411k worth of stock

Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic

New minor risk - Financial position

Summit Therapeutics Inc. to Report Q4, 2023 Results on Feb 20, 2024

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference

Co-CEO, President & Director exercised options to buy US$2.1m worth of stock.

Laura Chow Joins Summit Therapeutics Inc. as Senior Vice President of Clinical Development

Summit Therapeutics Inc. to Report Q3, 2023 Results on Nov 07, 2023

Lead Independent Director recently bought US$5.0m worth of stock

Summit Therapeutics Inc. Announces Executive Changes

First half 2023 earnings released: US$1.03 loss per share (vs US$0.38 loss in 1H 2022)

Summit Therapeutics Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

First quarter 2023 earnings released: US$1.43 loss per share (vs US$0.22 loss in 1Q 2022)

Summit Therapeutics Announces First Patient Treated in Phase III Harmoni Clinical Trial Evaluating Ivonescimab (SMT112)

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (Smt112)

Summit Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.41 loss per share (vs US$0.96 loss in FY 2021)

Summit Therapeutics Inc. Appoints Yu (Michelle) Xia as Member of the Board

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics Inc. Appoints Alessandra Cesano to Its Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 3Q 2021)

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics slips on plans to terminate study for lead candidate

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 loss in 2Q 2021)

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Summit Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $99.91 million.

Summit Therapeutics Appoints Maky Zanganeh as Co-CEO

Summit Therapeutics Provides Update on Ridinilazole

Summit to explore additional trial for its bacteria-induced colon infection drug

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 2000 Growth Index

Summit Therapeutics Inc. Appoints Ankur Dhingra as Chief Financial Officer

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.21 loss in 1Q 2021)

Summit Therapeutics Inc., Annual General Meeting, Jun 15, 2022

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Less than half of directors are independent

Less than half of directors are independent

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Summit Therapeutics Inc. Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

Summit Therapeutics Inc. Provides Update on Ri-CoDIFy Trials

Summit Therapeutics Presents Research Data from Phase II Studies, Including Evidence Validating Microbiome Preservation, for Its Investigational Drug Ridinilazole

Summit Therapeutics to Present Research Updates At the 31St Annual ECCMID Conference, Including A Top-Rated ePoster

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Summit Therapeutics to join Russell 3000 Index

Summit Therapeutics Inc. Announces Selected A New Preclinical Candidate, SMT026738

Summit Therapeutics Inc. Elects Dr. Michael Wang as Member of the Board

Summit Therapeutics Inc. Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics Inc. announced that it has received $50 million in funding from Polar Capital LLP and other investors

Summit Therapeutics Inc. announced that it expects to receive $50 million in funding

Summit Therapeutics Inc. Publishes Data from Its Phase 2 Clinical Trial of Ridinilazole Evaluating the Effects of A Narrow-Spectrum (Ridinilazole) or Broad-Spectrum Antibiotic

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento